drugset
drugset / Trial / NCT03397888

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

NCT03397888 ↗

Phase 1 Completed 32 enrolled Portola Pharmaceuticals
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Single center, prospective open label PK and PD study of betrixaban in subjects with mild and moderate hepatic impairment vs healthy volunteers.

Timeline

Start
2017-11-16
Primary completion
2018-01-16
Completion
2018-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Betrixaban Small molecule 80 mg Oral

Indications

No indication recorded.